Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …

Bruton's tyrosine kinase (BTK) is a critical downstream signaling element from the B-cell
receptor (BCR) that has been effectively inhibited in B-cell cancers by irreversible, covalent …

Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin's lymphoma with highly
heterogeneous clinical presentation and aggressiveness. First-line treatment consists of …

Acalabrutinib (ACL) was approved in the United States in the year of 2017 and 2019 for the
treatment of chronic lymphocytic leukemia (CLL) and relapsed mantle cell lymphoma (MCL) …

The improved understanding of lymphoma biology and recent advances in the field of
cancer immunology have paved the way for the development of many effective small …

Mantle cell lymphoma (MCL) is a rare B-cell malignancy that remains challenging to treat
with high rates of relapse. Frontline strategies range from intensive chemotherapy followed …

Greater understanding of the mechanisms involved in the disease progression of
haematological malignancies has led to the introduction of novel targeted therapies with …

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by
the overexpression of cyclin D1. MCL patients typically live for years but experience multiple …

Background Transformation of chronic lymphocytic leukaemia (CLL) to diffuse large B-cell
lymphoma (DLCBL) type Richter's syndrome (RS) carries a dismal prognosis. Standard-of …

Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma characterized
by an aggressive clinical course in the majority of patients. Despite recent improvements in …